medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2014, Number 4

<< Back Next >>

Ann Hepatol 2014; 13 (4)

Peginterferon alpha-2b plus ribavirin for chronic hepatitis C virus mixed genotype infection

Ching-Chung L, Chia-Hsien W, Huan-Lin C, I-Tsung L, Shen-Yung W, Tsang-En W, Horng-Yuan W, Shou-Chuan S, Ming-Jong B

Language: English
References: 22
Page: 350-355
PDF size: 108.77 Kb.


ABSTRACT

Background and aim. The treatment efficacy of peginterferon plus ribavirin for patients with HCV genotype 1 is inferior to that in patients with HCV genotype 2, but the efficacy among patients with mixed HCV genotype 1 + 2 is less clear. We compared the treatment outcome of peginterferon alpha-2b plus ribavirin among naïve chronic hepatitis C patients in Taiwan with HCV genotype 1 and 2, and mixed genotype 1 + 2. Material and methods. In this retrospective cohort study, 150 patients were treated with peginterferon alpha-2b once weekly, plus ribavirin, for 24 weeks. The endpoint was sustained virological response after receiving at least one dose of the study medication. Results. There were no differences in clinical characteristics among the 3 groups. There were significant differences in rapid virological response rate between patients with genotype 1 and genotype 2 (64.7 vs. 85.5%, respectively; p ‹ 0.05) and a sustained virological response rate (55.9 vs. 83.6%, respectively; p = 0.001). The rapid virological response rate differed between the genotype 1 and mixed genotype 1 + 2 groups (64.7 vs. 85.2%, respectively; p ‹ 0.05), but the sustained virological response rate was similar (55.9 vs. 74.1%; p = 0.101). Conclusions. Using peginterferon alpha-2b plus ribavirin for 24 weeks to treat patients with HCV genotype 1 + 2 achieved a 74.1% sustained virological response rate; the treatment efficacy was not inferior to patients with HCV genotype 1, but the percentage of liver cirrhosis in mixed genotype 1 + 2 group was higher to 22%, it is worth to be appropriately valued and studied.


REFERENCES

  1. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003; 362: 2095-100.

  2. Munir S, Saleem S, Idrees M, Tariq A, Butt S, Rauff B, Hussain A, et al. Hepatitis C treatment: current and future perspectives. Virol J 2010; 7: 296-312.

  3. Chen YD, Liu MY, Yu WL, Li JQ, Dai Q, Zhou ZQ, Tisminetzky SG, et al. Mix-infections with different genotypes of HCV and with HCV plus other hepatitis viruses in patients with hepatitis C in China. World J Gastroenterol 2003; 9: 984-92.

  4. Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol 2009; 24: 336-45.

  5. Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, Halfon P, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 962-73.

  6. Antonishyn NA, Ast VM, McDonald RR, Chaudhary RK, Lin L, Andonov AP, Horsman GB. Rapid genotyping of hepatitis C virus by primer-specific extension analysis. J Clin Microbiol 2005; 43: 5158-63.

  7. Prathiba K, Bagyalakshmi R, Malathi J, Anusha H, Ravichandran R, Chandy G, Madhavan HN. Optimization and application of subtype specific polymerase chain reaction for detection and identification of mixed subtypes of hepatitis C virus in patients with renal disease. J Virol Methods 2012; 186: 113-8.

  8. Hairul Aini H, Mustafa MI, Seman MR, Nasuruddin BA. Mixed-genotypes infections with hepatitis C virus in hemodialysis subjects. Med J Malaysia 2012; 67: 199- 203.

  9. Idrees M, Riazuddin S. Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission. BMC Infect Dis 2008; 69: 1471-2334-8-69.

  10. Toyoda H, Fukuda Y, Hayakawa T, Takayama T, Kumada T, Nakano S, Takamatsu J, et al. Characteristics of patients with chronic infection due to hepatitis C virus of mixed subtype: prevalence, viral RNA concentrations, and response to interferon therapy. Clin Infect Dis 1998; 26: 440-5.

  11. Ohno T, Mizokami M, Wu RR, Saleh MG, Ohba KI, Orito E, Mukaide M, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol 1997; 35: 201-7.

  12. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461(7262): 399-401.

  13. Yu ML, Huang CF, Huang JF, Chang NC, Yang JF, Lin ZY, Chen SC, et al. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 2011; 53: 7-13.

  14. Ahlenstiel G, Booth DR, George J. Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms? Antivir Ther 2012; 17: 1163-70.

  15. Blatt LM, Mutchnick MG, Tong MJ, Klion FM, Lebovics E, Freilich B, Bach N, et al. Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepat 2000; 7: 196-202.

  16. Ghany MG, Strader DB, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.

  17. Yu ML, Chuang WL, Dai CY, Lee LP, Hsieh MY, Lin ZY, Chen SC, et al. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy. Transl Res 2006; 148: 120-7.

  18. Neumann AU, Lam NP, Dahari H, Davidian M, Wiley TE, Mika BP, Perelson AS, et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000; 182: 28-35.

  19. Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, Lee LP, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008; 47: 1884-93.

  20. Petta S, Craxì A. How to optimize HCV therapy in genotype 1 patients: predictors of response. Liver Int 2013; 33(Suppl. 1): 23-9.

  21. Gidding HF, Law MG, Amin J, Ostapowicz G, Weltman M, Macdonald GA, Sasadeusz J, et al. Hepatitis C treatment outcomes in Australian clinics. Med J Aust 2012; 196: 633-7.

  22. Huang CF, Huang JF, Yang JF, Hsieh MY, Lin ZY, Chen SC, Wang LY, et al. Interleukin 28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. J Hepatol 2012; 56: 34-40.




2020     |     www.medigraphic.com